
Upstream Bio Announces Verekitug Trial Data
Upstream Bio (Nasdaq: UPB) will release top-line data from its Phase 2 VIBRANT trial of verekitug on September 2nd. The trial assessed the efficacy and safety of verekitug in adults with chronic rhinosinusitis with nasal polyps (CRSwNP). A conference call will follow the release.